Mast Therapeutics, Inc. (MSTX)

[pray]

Past track record.

If Epic successful could be a 10 bagger easy but there is a major downside. The CEO has been nothing but shady in the past. In the last five years there has been a name change, tripling of share structure, RS, dilution, not one successful drug product, multiple failures, 4 offerings and multiple dates when drug completion was changed. Add to that a CEO salary that has increased from $90,000 to over a million including bonuses and options with a stock dropping from $5.00 to the .30 cent range.